J

Joinn Laboratories China Co Ltd
SSE:603127

Watchlist Manager
Joinn Laboratories China Co Ltd
SSE:603127
Watchlist
Price: 39.95 CNY 7.31% Market Closed
Market Cap: ¥29.9B

EV/S

16
Current
147%
More Expensive
vs 3-y average of 6.5

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
16
=
Enterprise Value
¥24.3B
/
Revenue
¥1.7B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
16
=
Enterprise Value
¥24.3B
/
Revenue
¥1.7B

Valuation Scenarios

Joinn Laboratories China Co Ltd is trading above its 3-year average

If EV/S returns to its 3-Year Average (6.5), the stock would be worth ¥16.17 (60% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-79%
Maximum Upside
No Upside Scenarios
Average Downside
59%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 16 ¥39.95
0%
3-Year Average 6.5 ¥16.17
-60%
5-Year Average 10.3 ¥25.82
-35%
Industry Average 6.1 ¥15.35
-62%
Country Average 3.3 ¥8.24
-79%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
¥24.3B
/
Jan 2026
¥1.7B
=
16
Current
¥24.3B
/
Dec 2026
¥1.9B
=
12.9
Forward
¥24.3B
/
Dec 2027
¥2.2B
=
10.9
Forward
¥24.3B
/
Dec 2028
¥3B
=
8.1
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
CN
Joinn Laboratories China Co Ltd
SSE:603127
29.9B CNY 16 100.5
US
PerkinElmer Inc
LSE:0KHE
936.1B USD 328.4 3 881
US
Thermo Fisher Scientific Inc
NYSE:TMO
173.3B USD 4.6 25.3
US
Danaher Corp
NYSE:DHR
126.5B USD 5.6 34.3
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 17.9 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
329.9B CNY 6.5 17.3
CH
Lonza Group AG
SIX:LONN
33.1B CHF 5.5 -118.7
US
Agilent Technologies Inc
NYSE:A
31.5B USD 4.7 24.4
US
Waters Corp
NYSE:WAT
28.7B USD 9.2 44.6
US
IQVIA Holdings Inc
NYSE:IQV
26.6B USD 2.4 19.6
US
Mettler-Toledo International Inc
NYSE:MTD
25.2B USD 6.8 29

Market Distribution

Higher than 91% of companies in China
Percentile
91th
Based on 7 593 companies
91th percentile
16
Low
0 — 1.7
Typical Range
1.7 — 6.2
High
6.2 —
Distribution Statistics
China
Min 0
30th Percentile 1.7
Median 3.3
70th Percentile 6.2
Max 5 034 353.9

Joinn Laboratories China Co Ltd
Glance View

Nestled in the bustling heart of China's vibrant biomedical sector, Joinn Laboratories China Co Ltd has emerged as a pivotal player in advancing the field of pharmaceutical research and development. Founded with a vision to revolutionize the landscape of drug testing and safety evaluation, Joinn Laboratories operates as a comprehensive preclinical contract research organization (CRO). The company specializes in providing a wide array of services including toxicology, pharmacology, and bioanalytical testing that are crucial in the early stages of drug development. With an expansive network of state-of-the-art laboratories and a team of highly skilled scientists, Joinn facilitates the essential task of ensuring that pharmaceutical products meet rigorous safety and efficacy standards before advancing to clinical trials. Joinn Laboratories generates revenue primarily by offering these indispensable services to pharmaceutical companies and biotech firms worldwide. By acting as an external testing partner, Joinn allows its clients to significantly streamline their drug development processes, reducing both time and cost associated with bringing a new drug to market. Their business model thrives on the growing demand for outsourced R&D capabilities, a trend fueled by the increasing complexity and regulatory requirements in drug approval processes. The company leverages its expertise and cutting-edge technology to deliver precise and reliable data, thus providing a seamless bridge between scientific discovery and market-ready pharmaceutical solutions.

Intrinsic Value
7.69 CNY
Overvaluation 81%
Intrinsic Value
Price ¥39.95
J
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett